非小细胞肺癌患者凝血功能变化与肿瘤恶性程度相关性分析

doi:10.3877/cma.j.issn.1674-6902.2019.05.006

目的

探讨非小细胞肺癌凝血指标、血小板计数的变化与肿瘤病理类型、分期、淋巴结及血行转移的关系，为临床预测和判断肺癌患者病情进展和转移情况提供依据。

方法

选择2017年1月至2018年10月在本院接受治疗的99例非小细胞肺癌(NSCLC)患者作为观察组，同期体检健康人群40例作为对照组。将观察组根据患者病理类型分为鳞癌组(23例)、腺癌组(76例)，分析两组研究对象的凝血功能、D-二聚体及血小板，及临床意义，并对比分析不同临床病理类型及分期患者凝血功能的变化情况。

结果

与对照组相比，观察组PT(P<0.001)、INR(P<0.001)明显缩短，而FIB(P<0.001)、D-D(P<0.001)则明显升高；对观察组临床病理类型及分期患者分析发现，鳞癌比腺癌PT(P<0.001)、FIB(P＝0.002)、APTT(P＝0.028)、INR(P＝0.043)水平升高；与Ⅰ-Ⅲ期患者相比，Ⅳ期患者PT(P<0.001)、FIB(P<0.001)、APTT(P<0.001)升高；与N0患者相比，N1-3患者PT(P<0.001)、FIB(P<0.001)、APTT(P<0.001)升高；有无肺/胸膜外转移患者凝血指标水平差异无统计学意义(P>0.05)。临床获益组化疗后与化疗前比较，PT、INR、D-D缩短(P＝0.007，P＝0.036，P＝0.034)，TT延长(P＝0.013)。进展组化疗前后凝血指标水平差异无统计学意义。

结论

NSCLC患者凝血功能普遍存在异常，且与病理类型、肿瘤分期具有一定的相关性，肺鳞癌、分期为晚期以及存在淋巴结转移的患者更易出现高凝状态；对于临床获益组而言，化疗可以使PT、INR缩短，TT延长，增加血栓事件发生的风险。

关键词: 非小细胞肺癌, 凝血功能, 化疗, 临床意义

Objective

To analyze the relationship between the coagulation function changes and the malignancy degrees in the patients with non-small cell lung cancer (NSCLC) in order to provide bases for clinical prediction and judgment of the progress and metastasis of lung cancer patients.

Methods

In this study, 99 patients with NSCLC who were treated in our hospital from January 2017 to October 2018 were taken as a case group (the NSCLC group) and 40 healthy subjects in the same period were taken as a control group. According to the pathological type, the case group was divided into a squamous cell carcinoma group (n=23 cases) and an adenocarcinoma group (n=76 cases). A total of 50 patients had no lymph node metastasis and 49 had lymph node metastasis. Fourteen patients had no extra-lung/pleural metastasis and 13 had lung/pleural metastasis. According to the Eighth Edition of Lung Cancer TNM Staging, stage Ⅰ was found in 26 cases, stage Ⅱ in 22, stage Ⅲ in 24, and stage Ⅳ in 27. The patients with stage Ⅲ and stage Ⅳ lung cancer were divided into a clinical benefit group (n=42 cases) and a clinical progression group (n=9 cases), respectively, after two courses of conventional chemotherapy. The coagulation function, D-dimer and platelet count were detected in the two groups, and their clinical significance was analyzed. The changes of coagulation function under different clinical and pathological factors were compared and analyzed.

Results

Compared with the control group, the prothrombin time (PT, P<0.001) and the international normalized ratio (INR, P<0.001) were significantly shortened in the NSCLC group, while the fibrinogen (FIB, P<0.001) and the thrombin time (D-D, P<0.001) were significantly increased. Group analysis of the clinical and pathological factors in the patients with NSCLC found that PT (P<0.001), FIB (P=0.002), the activated partial thromboplastin time (APTT, P=0.028) and INR (P=0.043) were higher in the patients with squamous cell carcinoma than in the patients with adenocarcinoma. The levels of PT (P<0.001), FIB (P<0.001) and APTT (P<0.001) increased in stage Ⅳ patients with NSCLC compared with those of stage Ⅰ-Ⅲ patients. The levels of PT (P<0.001), FIB (P<0.001) and APTT (P<0.001) increased in N1-3 patients with NSCLC compared with those of the controls. There was no significant difference in blood coagulation indexes between the patients with or without extra-lung/pleural metastasis (P>0.05). In the clinical benefit group, PT, INR and D-D were shortened (P=0.007, P=0.036, and P=0.034, respectively) and TT increased (P=0.013) after chemotherapy compared with those before chemotherapy. There was no significant difference in the level of coagulation indexes between the clinical advanced group.

Conclusion

The coagulation function of the patients with NSCLC is generally abnormal and it has a certain correlation with the pathological type and the tumor stage. The patients with lung squamous cell carcinoma, in the advanced stage and with lymph node metastasis are more prone to hypercoagulability. PT and INR shortening and TT prolongation can be used as an early indicator of the efficacy of chemotherapy in the patients with NSCLC and can increase the occurrence of thrombotic events.

Key words: Non-small cell lung cancer, Coagulation, Chemotherapy, Clinical significance

表1 两组凝血功能相关指标的比较

凝血指标	例数	PT(s)	FiB(g/L)	TT(s)	APTT(s)	INR	D-D(mg/L)	PLT(10⁹/L)
NSCLC组	99	12.39±0.97	3.20(2.71～4.32)	17.55±1.29	34.70(28.50～39.10)	0.99(0.95～1.05)	0.60(0.38～0.87)	197.90±68.24
对照组	40	13.09±1.15	2.08(1.82～2.27)	17.75±0.97	33.00(29.03～37.83)	1.12(1.04～1.17)	0.16(0.10～0.27)	217.65±51.43
t或Z值		-3.64	-7.08	-0.89	-0.43	-6.29	-6.27	-1.31
P值		0	0	0.373	0.67	0	0	0.194

表1 两组凝血功能相关指标的比较

凝血指标	例数	PT(s)	FiB(g/L)	TT(s)	APTT(s)	INR	D-D(mg/L)	PLT(10⁹/L)
NSCLC组	99	12.39±0.97	3.20(2.71～4.32)	17.55±1.29	34.70(28.50～39.10)	0.99(0.95～1.05)	0.60(0.38～0.87)	197.90±68.24
对照组	40	13.09±1.15	2.08(1.82～2.27)	17.75±0.97	33.00(29.03～37.83)	1.12(1.04～1.17)	0.16(0.10～0.27)	217.65±51.43
t或Z值		-3.64	-7.08	-0.89	-0.43	-6.29	-6.27	-1.31
P值		0	0	0.373	0.67	0	0	0.194

表2 NSCLC患者临床病理特征与凝血功能相关指标的关系

临床病理特征		凝血指标(中位数)
临床病理特征		PT(s)	FiB(g/L)	TT(s)	APTT(s)	INR	D-D(mg/L)	PLT(10⁹/L)
病理类型
	鳞癌	13.10	4.24	17.30	37.30	1.03	0.58	185.00
	腺癌	12.20	3.09	17.45	33.20	0.98	0.62	206.00
	t或Z值	4.12	-3.11	-0.04	-2.20	-2.03	-0.46	-0.53
	P值	0.000	0.002	0.967	0.028	0.043	0.643	0.590
TNM分期
	Ⅰ	11.75	2.76	17.30	29.00	0.98	0.27	209.50
	Ⅱ	11.65	2.94	17.70	30.85	0.98	0.45	219.50
	Ⅲ	13.10	3.47	17.65	36.90	1.03	0.56	206.50
	Ⅳ	12.90	4.32	17.30	38.70	0.99	0.68	189.00
	F或χ²值	20.61	30.52	5.89	26.06	5.19	7.55	0.26
	P值	0.000	0.000	0.117	0.000	0.158	0.056	0.856
淋巴结转移
	N0	11.80	2.93	17.35	30.40	0.98	0.45	209.50
	N1～N3	12.90	3.61	17.50	37.80	1.00	0.62	193.00
	t或Z值	-5.44	-4.31	-0.20	-4.40	-1.25	-0.83	0.39
	P值	0.000	0.000	0.842	0.000	0.221	0.406	0.696
远处转移
	肺/胸膜	12.80	4.32	17.40	35.40	0.97	0.62	193.00
	肺/胸膜外	13.00	3.54	17.20	36.90	1.01	0.68	232.00
	t或Z值	-0.22	-0.62	1.21	-0.11	-0.56	-0.74	-0.94
	P值	0.826	0.538	0.234	0.913	0.574	0.460	0.345

表2 NSCLC患者临床病理特征与凝血功能相关指标的关系

临床病理特征		凝血指标(中位数)
临床病理特征		PT(s)	FiB(g/L)	TT(s)	APTT(s)	INR	D-D(mg/L)	PLT(10⁹/L)
病理类型
	鳞癌	13.10	4.24	17.30	37.30	1.03	0.58	185.00
	腺癌	12.20	3.09	17.45	33.20	0.98	0.62	206.00
	t或Z值	4.12	-3.11	-0.04	-2.20	-2.03	-0.46	-0.53
	P值	0.000	0.002	0.967	0.028	0.043	0.643	0.590
TNM分期
	Ⅰ	11.75	2.76	17.30	29.00	0.98	0.27	209.50
	Ⅱ	11.65	2.94	17.70	30.85	0.98	0.45	219.50
	Ⅲ	13.10	3.47	17.65	36.90	1.03	0.56	206.50
	Ⅳ	12.90	4.32	17.30	38.70	0.99	0.68	189.00
	F或χ²值	20.61	30.52	5.89	26.06	5.19	7.55	0.26
	P值	0.000	0.000	0.117	0.000	0.158	0.056	0.856
淋巴结转移
	N0	11.80	2.93	17.35	30.40	0.98	0.45	209.50
	N1～N3	12.90	3.61	17.50	37.80	1.00	0.62	193.00
	t或Z值	-5.44	-4.31	-0.20	-4.40	-1.25	-0.83	0.39
	P值	0.000	0.000	0.842	0.000	0.221	0.406	0.696
远处转移
	肺/胸膜	12.80	4.32	17.40	35.40	0.97	0.62	193.00
	肺/胸膜外	13.00	3.54	17.20	36.90	1.01	0.68	232.00
	t或Z值	-0.22	-0.62	1.21	-0.11	-0.56	-0.74	-0.94
	P值	0.826	0.538	0.234	0.913	0.574	0.460	0.345

表3 NSCLC临床获益组化疗前后凝血功能相关指标比较

凝血指标范围		PT(s)11-15	FIB(g/L)2-4	TT(s)14-21	APTT(s)28-44	INR0．75-1.25	D-D(mg/L)0-0.50	PLT(10⁹/L)150-350
化疗前(n＝43)		12.95(12.50～13.50)	3.70(3.15～5.01)	17.40(16.10～18.20)	37.55(34.90～40.83)	1.01(0.95～1.05)	0.61(0.42～0.81)	189.50(146.75～235.75)
化疗后(n＝43)		12.65(12.20～13.13)	3.92(3.37～4.88)	17.50(17.00～18.30)	36.45(34.08～41.23)	0.96(0.93～1.04)	0.71(0.50～1.12)	187.50(154.75～274.00)
	t或Z值	-2.69	-1.83	-2.60	-1.00	-2.10	-2.11	-1.48
	P值	0.007	0.068	0.013	0.317	0.036	0.034	0.139

表3 NSCLC临床获益组化疗前后凝血功能相关指标比较

凝血指标范围		PT(s)11-15	FIB(g/L)2-4	TT(s)14-21	APTT(s)28-44	INR0．75-1.25	D-D(mg/L)0-0.50	PLT(10⁹/L)150-350
化疗前(n＝43)		12.95(12.50～13.50)	3.70(3.15～5.01)	17.40(16.10～18.20)	37.55(34.90～40.83)	1.01(0.95～1.05)	0.61(0.42～0.81)	189.50(146.75～235.75)
化疗后(n＝43)		12.65(12.20～13.13)	3.92(3.37～4.88)	17.50(17.00～18.30)	36.45(34.08～41.23)	0.96(0.93～1.04)	0.71(0.50～1.12)	187.50(154.75～274.00)
	t或Z值	-2.69	-1.83	-2.60	-1.00	-2.10	-2.11	-1.48
	P值	0.007	0.068	0.013	0.317	0.036	0.034	0.139

表4 NSCLC临床进展组化疗前后凝血功能相关指标的比较

凝血指标范围		PT(s)11-15	FIB(g/L)2-4	TT(s)14-21	APTT(s)28-44	INR0．75-1.25	D-D(mg/L)0-0.50	PLT(10⁹/L)150-350
化疗前(n＝9)		12.67±1.14	4.29±1.55	17.24±1.19	34.82±7.26	1.04±0.08	1.54±1.41	233.33±59.20
化疗后(n＝9)		12.87±0.93	4.05±0.82	17.88±1.40	38.22±5.36	0.98±0.11	1.48±1.70	239.44±87.35
	t值	-0.62	0.62	-1.27	-1.33	1.54	0.12	-0.22
	P值	0.554	0.554	0.240	0.219	0.162	0.908	0.831

表4 NSCLC临床进展组化疗前后凝血功能相关指标的比较

凝血指标范围		PT(s)11-15	FIB(g/L)2-4	TT(s)14-21	APTT(s)28-44	INR0．75-1.25	D-D(mg/L)0-0.50	PLT(10⁹/L)150-350
化疗前(n＝9)		12.67±1.14	4.29±1.55	17.24±1.19	34.82±7.26	1.04±0.08	1.54±1.41	233.33±59.20
化疗后(n＝9)		12.87±0.93	4.05±0.82	17.88±1.40	38.22±5.36	0.98±0.11	1.48±1.70	239.44±87.35
	t值	-0.62	0.62	-1.27	-1.33	1.54	0.12	-0.22
	P值	0.554	0.554	0.240	0.219	0.162	0.908	0.831

1	钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2	Kiyokara C, Yoshimasu K, Takayama K, et al. Lung cancer susceptibility：are we on our way to identifying a high-risk group？[J]. Future Oncol, 2016, 3(6): 617-627.
3	Cohen AT, Katholing A, Rietbrock S, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study[J]. Thromb Haemost, 2017, 117(1): 57-65.
4	Lin Y, Liu Z, Qiu Y, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: A systematic review and meta-analysis[J]. Eur J Surg Oncol, 2018, 44(10): 1494-1503.
5	Donnellan E, Khorana AA. Cancer and venous thromboembolic disease：a review[J]. Oncologist, 2017, 22(2): 199-207.
6	Zhu LR, Li J, Chen P, et al. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients[J]. Clin Transl Oncol, 2016, 18(2): 178-188.
7	Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis[J]. Blood, 2017, 130(13): 1499-1506.
8	Farge D, Frere C. Recent advances in the treatment and prevention of venous thromboembolism in cancerpatients: role of the direct oral anticoagulants and their unique challenges[J]. F1000Res, 2019, 8: doi: 10.12688/f1000research.18673.1.
9	Thein KZ, Myint ZW, Tun AM, et al. Cancer Associated Thrombosis：Focus on Prevention and Treatment of Venous Thromboembolism[J]. Cardiovasc Hematol Agents Med Chem, 2016, 2(14): 101-112.
10	Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond[J]. Crit Rev Clin Lab Sci, 2016, 53(6): 409-430.
11	Wakatsuki K, Matsumoto S, Migita K, et al. Prognostic value of the fibrinogen-to-platelet ratio as an inflammatory and coagulative index in patients with gastric cancer[J]. Surg Today, 2019, 49(4): 334-342.
12	Suzuki T, Shimada H, Nanami T, et al. Hyperfibrinogenemia is associated with inflammatory mediators and poor prognosis in patientswith gastric cancer[J]. Surg Today, 2016, 46(12): 1394-1401.
13	Ay C, Pabinger I. VTE risk assessment in cancer. Who needs prophylaxis and who does not？[J]. Hamostaseologie, 2015, 35(4): 319-324.
14	Fernandes CJ, Morinaga LTK, Alves JL Jr, et al. Cancer-associated thrombosis: the when, how and why[J]. Eur Respir Rev, 2019, 27: 28(151)：doi: 10.1183/16000617.0119-2018.
15	Vedovati MC, Giustozzi M, Becattini C．Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants[J]. Thromb Res, 2019, 177: 33-41.
16	Ji R, Ren Q, Bai S, et al. Prognostic significance of retreatment plasma fibrinogen level in patients with digestivesystem tumors: a meta-analysis[J]. Int J Biol Markers, 2018, 33(3): 254-265.
17	Hisada Y, Geddings JE, Ay C, et al. Venous thrombosis and cancer：from mouse models to clinical trials[J]. J Thromb Haemost, 2015, 13(8): 1372-1382.
18	Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models[J]. Cancers (Basel), 2019, 11(1): doi: 10.3390/cancers11010095.
19	Mendonça L, Trindade A, Carvalho C, et al. Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells[J]. Clin Exp Metastasis, 2019, 36(4): 365-380.
20	Li W, Tang Y, Song Y, et al. Prognostic Role of Pretreatment Plasma D-Dimer in Patients with Solid Tumors: a Systematic Review and Meta-Analysis[J]. Cell Physiol Biochem, 2018, 45(4): 1663-1676.
21	Tieken C, Versteeg HH. Anticoagulants versus cancer[J]. Thromb Res, 2016, 140 (Suppl 1): S148-S153.
22	Crous-Bou M．, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism[J]. Semin Thromb Hemost, 2016, 42: 808-820.
23	Walker AJ, Baldwin DR, Card TR, et al. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data[J]. Br J Cancer, 2016, 115(1): 115-121.
24	龚长艳，李智文，周德训，等. 肺癌患者症状性静脉血栓栓塞症危险因素分析[J]. 中华结核和呼吸杂志，2016, 39(6): 454-458.
25	Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study[J]. Oncologist, 2017, 22(10): 1222-1231.
26	Kuderer NM, Poniewierski MS, Culakova E. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK) [J]. Oncologist, 2018, 23(2): 247-255.

[1]	洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J]. 中华医学超声杂志（电子版）, 2024, 21(06): 571-579.
[2]	赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J]. 中华医学超声杂志（电子版）, 2024, 21(04): 361-369.
[3]	杨焕, 马靓, 沈俊, 董丽丽, 孙文雯. 乳腺癌新辅助化疗患者支持性照顾需求与症状群及应对方式的相关性[J]. 中华乳腺病杂志(电子版), 2024, 18(04): 224-230.
[4]	许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[5]	马立伟, 贾志强, 陈午盛, 邵明亮, 刘琼, 段玉松. CalliSpheres载药微球联合碘化油治疗肝癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 369-372.
[6]	达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[7]	宋小飞, 巫嘉文, 孙阳. 输尿管开口周围膀胱黏膜预离断联合早期膀胱灌注化疗在上尿路尿路上皮癌根治术中的应用[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 479-484.
[8]	陶银花, 张红杰, 王亚岚, 陈莲, 张珺. 间歇式气压治疗预防肺癌化疗下肢深静脉血栓的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 605-608.
[9]	赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[10]	张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[11]	张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[12]	王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[13]	李永政, 孟煜凡, 樊知遥, 展翰翔. 胰腺神经内分泌肿瘤新辅助治疗研究进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 481-486.
[14]	张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
[15]	赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 基于自动乳腺超声的列线图模型早期预测HER-2阳性乳腺癌新辅助化疗病理完全缓解的临床价值[J]. 中华临床医师杂志(电子版), 2024, 18(04): 355-362.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Relevance analysis of coagulation function changes and malignancy degrees in patients with non-small cell lung cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Relevance analysis of coagulation function changes and malignancy degrees in patients with non-small cell lung cancer